Osteoporosis prevention, screening, and treatment: A review

Journal of Women's Health

Volumn 23, Issue 7, 2014, Pages 563-572

  Kling, Juliana M ^a   Clarke, Bart L ^b   Sandhu, Nicole P ^b  

^a MAYO CLINIC HOSPITAL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DENOSUMAB; PARATHYROID HORMONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D;

AGILITY; ALGORITHM; ARTICLE; BODY EQUILIBRIUM; BODY POSTURE; BONE DENSITOMETRY; BONE DENSITY; BONE TURNOVER; DECISION MAKING; ETHNIC GROUP; FALLING; FRACTURE RISK ASSESSMENT TOOL; FRAGILITY FRACTURE; GENERAL PRACTITIONER; HIGH RISK POPULATION; HIP FRACTURE; HORMONAL THERAPY; HUMAN; MASS SCREENING; MUSCLE FUNCTION; OSSIFICATION; OSTEOPOROSIS; PATIENT CARE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESISTANCE TRAINING; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; VITAMIN SUPPLEMENTATION;

ABSORPTIOMETRY, PHOTON; AGED; BONE DENSITY; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; MASS SCREENING; OSTEOPOROSIS; RISK ASSESSMENT;

EID: 84904353104     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2013.4611     Document Type: Article

References (71)

1. National Osteoporosis Foundation. America's bone health: The state of osteoporosis and low bone mass in our nation. Washington, DC: The Foundation 2002; 1-55.
2. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-475. (Pubitemid 46797130)
3. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2010;1-56.
4. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005;16:S3-S7. (Pubitemid 46232115)
5. World Health Organization. WHO Scientific Group on the assessment of osteoporosis at primary health care level: Summary meeting report; May 5-7, 2004, Brussels, Belgium. Geneva, Switzerland: World Health Organization 2007; 1-17.
6. McCloskey EV, Vasireddy S, et al. Vertebral fracture assessment (VFA) with a densitometer predicts future fractures in elderly women unselected for osteoporosis. J Bone Miner Res 2008;23:1561-1568.
7. World Health Organization (WHO) Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report No. 843. Geneva, Switzerland: World Health Organization, 1994;1-134.
8. Lewiecki EM, Watts NB, McLund MR, et al. Official positions of the International Society for Clinical Densito-metry. JCEM 2004;89:3651-3655. (Pubitemid 39071449)
9. Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement. 2000;17:1-45.
10. Howe TE, Shea B, Dawson LJ, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2011;7:CD000333.
11. The North American Menopause Society (NAMS). Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010:17;23-24.
12. Lim LS, Hoeksema LJ, Sherin K; ACPM Prevention Practice Committee. Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Am J Prev Med 2009;36:366-375.
13. U.S. Preventive Services Task Force. Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med 2011;154:356-364.
14. Florence R, Allen S, Benedict L, Compo R, Jensen A, Kalogeropoulou D, et al. Diagnosis and treatment of osteoporosis. Bloomington, MN: Institute for Clinical Systems Improvement, 2013.
15. Gourlay ML, Fine JP, Preisser JS, et al. Study of Osteo-porotic Fractures Research Group. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med 2012;366:225-233.
16. U.S. Preventive Services Task Force (USPSTF). Vitamin D and calcium supplementation to prevent fractures. Rockville, MD: USPSTF, 2013. Available at: www.uspreventiveservices taskforce.org/uspstf/uspsvitd.htm Accessed May 2013.
17. Institute of Medicine (IOM). Dietary reference intakes for calcium and vitamin D. Washington DC: National Academy of Sciences, 2010. Available at: www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D. aspx Accessed August 2012
18. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington, DC: National Academy of Sciences, 1997.
19. Cranney A, Weiler HA, O'Donnell S, Puil L. Summary of evidence-based review on vitamin D efficacy and safety in relation to bone health. Am J Clin Nutr 2008;88:513S-519S.
20. Foley KF, Boccuzzi L. Urine calcium: laboratory measurement and clinical utility. Lab Med 2010;41:683-686.
21. Jackson RD, LaCroix AZ, Gass M, et al.; Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354:669-683. Erratum in: N Engl J Med. 2006; 354:1102. (Pubitemid 43247138)
22. Vacek JL, Vanga SR, Good M, Lai SM, Lakkireddy D, Howard PA. Vitamin D deficiency and supplementation and relation to cardiovascular health. Am J Cardiol 2012;109:359-363.
23. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008;117:503-511.
24. Lutsey PL, Michos ED. Vitamin D, calcium, and atherosclerotic risk: Evidence from serum levels and supplementation studies. Curr Atheroscler Rep 2013;15:293.
25. LaCroix AZ, Kotchen J, Anderson G, et al. Calcium plus vitamin D supplementation and mortality in postmeno-pausal women: The Women's Health Initiative calcium-vitamin D randomized controlled trial. J Gerontol A Biol Sci Med Sci 2009;64:559-567.
26. Cauley JA, Chlebowski RT, Wactawski-Wende J, et al. Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: The Women's Health Initiative. J Womens Health (Larchmt) 2013;22:915-929.
27. Michaelsson K, Melhus H, Warensjo Lemming E, Wolk A, Byberg L. Long term calcium intake and rates of all cause and cardiovascular mortality: Community based prospective longitudinal cohort study. BMJ 2013;346:f228.
28. Rossouw JE, Anderson GL, Prentice RL, et al.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
29. Chung M, Balk EM, Brendel M, et al. Vitamin D and calcium: A systematic review of health outcomes. Evidence Reports/Technology Assessments, No. 183. Rockville, MD: Agency for Healthcare Research and Quality, 2009.
30. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670-676. (Pubitemid 27375473)
31. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637-1642.
32. Tucker KL, Jugdaohsingh R, Powell JJ, et al. Effects of beer, wine, and liquor intakes on bone mineral density in older men and women. Am J Clin Nutr 2009;89:1188-1196.
33. Sommer I, Erkkila AT, Jarvinen R, et al. Alcohol consumption and bone mineral density in elderly women. Public Health Nutr 2013;16:70-7-12.
34. Kanis JA, Hans D, Cooper C, et al; Task Force of the FRAX Initiative. Interpretation and use of FRAX in clinical practice. Osteoporos Int 2011;22:2395-411.
35. Abrahamsen B. Screening: FRAX in clinical practice. Nat Rev Rheumatol 2011;7:686-688.
36. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA 2002;288:1889-1897. Erratum in: JAMA 2002;288:2825. (Pubitemid 35168145)
37. Kern LM, Powe NR, Levine MA, et al. Association between screening for osteoporosis and the incidence of hip fracture. Ann Intern Med 2005;142:173-181. (Pubitemid 40189109)
38. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures: The study of Osteoporotic Fractures Research Group. Lancet 1993; 341:72-75. (Pubitemid 23028113)
39. Leslie WD, Tsang JF, Caetano PA, Lix LM; Manitoba Bone Density Program. Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab 2007;92:77-81. (Pubitemid 46067512)
40. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148:197-213. (Pubitemid 351665507)
41. Hillier TA, Stone KL, Bauer DC, et al. Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: The study of osteoporotic fractures. Arch Intern Med 2007;167:155-160. (Pubitemid 46148062)
42. Frost SA, Nguyen ND, Center JR, Eisman JA, Nguyen TV. Timing of repeat BMD measurements: Development of an absolute risk-based prognostic model. J Bone Miner Res 2009;24:1800-1807.
43. Nayak S, Roberts MS, Greenspan SL. Cost-effectiveness of different screening strategies for osteoporosis in postmen-opausal women. Ann Intern Med. 2011;155:751-761.
44. Hosking D, Adami S, Felsenberg D, et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin 2003; 19:383-394. (Pubitemid 37006371)
45. Downs RW Jr, Bell NH, Ettinger MP, et al. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 2000;85:1783-1788. (Pubitemid 32269276)
46. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;1:CD001155.
47. Anastasilakis AD, Goulis DG, Kita M, Avramidis A. Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases. Hormones (Athens) 2007;6:233-241.
48. Lewiecki EM. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. J Womens Health (Larchmt) 2009;18:1615-1626.
49. Munoz-Torres M, Alonso G, Raya MP. Calcitonin therapy in osteoporosis. Treat Endocrinol 2004;3:117-132. (Pubitemid 38337562)
50. Cummings SR, San Martin J, McClung MR, et al; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-765. Erratum in: N Engl J Med. 2009; 361:1914.
51. Rimes KA, Salkovskis PM. Prediction of psychological reactions to bone density screening for osteoporosis using a cognitive-behavioral model of health anxiety. Behav Res Ther 2002;40:359-381. (Pubitemid 34226598)
52. Wainwright SA, Marshall LM, Ensrud KE, et al; Study of Osteoporotic Fractures Research Group. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 2005;90:2787-2793. (Pubitemid 40686325)
53. Schuit SC, van der Klift M, Weel AE, et al. Fracture incidence and association with bone mineral density in elderly men and women: The Rotterdam Study. Bone 2004;34:195-202. Erratum in: Bone 2006;38:603. (Pubitemid 38142449)
54. Brown JP, Josse RG; Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167:S1-S34. Errata in: CMAJ. 2003;168:400. CMAJ 2003;168:676. CMAJ 2003;168:544. (Pubitemid 35365303)
55. Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis: Executive summary. Osteoporos Int 1998;8:S3-S6.
56. Nelson HD, Haney EM, Dana T, Bougatsos C, Chou R. Screening for osteoporosis: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2010;153:99-111.
57. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alen-dronate. N Engl J Med 2008;358:1304-1306. (Pubitemid 351439247)
58. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. Bone 2010;47:169-180.
59. Girgis CM, Seibel MJ. Atypical femur fractures: a review of the evidence and its implication to clinical practice. Ther Adv Musculoskelet Dis 2011;3:301-314.
60. McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, et al. Bisphosphonate therapy for osteoporosis: Benefits, risks, and drug holiday. Am J Med 2013;126:13-20.
61. Komm BS, Chines AA. An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis. Maturitas 2012;71:221-226.
62. Siminoski K, Josse RG. Prevention and management of osteoporosis: Consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada: 9, calcitonin in the treatment of osteoporosis. CMAJ 1996;155:962-965
63. In brief: Cancer risk with salmon calcitonin. Med Lett Drugs Ther 2013;55:29.
64. Krum SA, Brown M. Unraveling estrogen action in osteoporosis. Cell Cycle 2008;7:1348-1352. (Pubitemid 351872572)
65. Peterson JA. Osteoporosis overview. Geriatr Nurs 2001; 22:17-21. (Pubitemid 33378242)
66. Bergmann P, Body JJ, Boonen S, et al; Members of Advisory Board on Bone Markers. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: A consensus document of the Belgian Bone Club. Int J Clin Pract 2009;63:19-26.
67. Vasikaran SD. Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosis. Crit Rev Clin Lab Sci 2008;45:221-258. (Pubitemid 351544135)
68. Lee J, Vasikaran S. Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Ann Lab Med 201232:105-112. Erratum in: Ann Lab Med 2012;32:242.
69. National Osteoporosis Foundation (NOF). Learn about osteoporosis. Washington, DC: National Osteoporosis Foundation. Available from: www.nof.org/node/40 Accessed August15, 2012.
70. Looker AC, Johnston CC Jr, Wahner HW, et al. Prevalence of low femoral bone density in older U.S. women from NHANES III. J Bone Miner Res 1995;10:796-802.
71. Hamrick I, Cao Q, Agbafe-Mosley D, Cummings DM. Osteoporosis healthcare disparities in postmenopausal women. J Womens Health (Larchmt) 2012;21:1232-1236.